Works matching DE "SIPULEUCEL-T (Drug)"
Results: 53
Rush Hour Traffic: Directing T Cells to Tumor.
- Published in:
- 2014
- By:
- Publication type:
- Editorial
Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 11, p. 1, doi. 10.1093/jnci/dju268
- By:
- Publication type:
- Article
Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.
- Published in:
- Prostate Cancer & Prostatic Diseases, 2014, v. 17, n. 3, p. 259, doi. 10.1038/pcan.2014.21
- By:
- Publication type:
- Article
Therapy for Castration-Resistant Prostate Cancer: Use Disease State as the Guide.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 3, p. 173
- Publication type:
- Article
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models.
- Published in:
- Frontiers in Immunology, 2015, p. 1, doi. 10.3389/fimmu.2015.00243
- By:
- Publication type:
- Article
Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer.
- Published in:
- ImmunoTargets & Therapy, 2017, v. 6, p. 11, doi. 10.2147/ITT.S122497
- By:
- Publication type:
- Article
Therapeutic cancer vaccines and combination immunotherapies involving vaccination.
- Published in:
- ImmunoTargets & Therapy, 2014, v. 3, p. 135, doi. 10.2147/ITT.S40264
- By:
- Publication type:
- Article
Real-World Treatment Patterns in Patients with Castrate-Resistant Prostate Cancer and Bone Metastases.
- Published in:
- American Health & Drug Benefits, 2019, v. 12, n. 3, p. 142
- By:
- Publication type:
- Article
Novel agents in the management of castration resistant prostate cancer.
- Published in:
- Journal of Carcinogenesis, 2014, v. 13, n. 1, p. 1, doi. 10.4103/1477-3163.128185
- By:
- Publication type:
- Article
Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration's Adverse Event Reporting System, 2010-2017.
- Published in:
- JAMA Network Open, 2019, v. 2, n. 8, p. e199249, doi. 10.1001/jamanetworkopen.2019.9249
- By:
- Publication type:
- Article
Postmarketing Analysis of Sipuleucel-T—The Importance of Real-World Data.
- Published in:
- 2019
- By:
- Publication type:
- Opinion
Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer.
- Published in:
- JAMA Network Open, 2019, v. 2, n. 4, p. e192589, doi. 10.1001/jamanetworkopen.2019.2589
- By:
- Publication type:
- Article
Immunotherapy for Prostate Cancer Enters Its Golden Age.
- Published in:
- Clinical Medicine Insights: Oncology, 2012, n. 6, p. 263, doi. 10.4137/CMO.S7475
- By:
- Publication type:
- Article
Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer.
- Published in:
- OncoTargets & Therapy, 2014, v. 7, p. 223, doi. 10.2147/OTT.S53524
- By:
- Publication type:
- Article
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.
- Published in:
- Journal of Hematology & Oncology, 2012, v. 5, n. 1, p. 35, doi. 10.1186/1756-8722-5-35
- By:
- Publication type:
- Article
Immunotherapy in Prostate Cancer.
- Published in:
- Üroonkoloji Bülteni, 2019, v. 18, n. 2, p. 67, doi. 10.4274/uob.galenos.2018.1142
- By:
- Publication type:
- Article
The treatment of metastatic prostate cancer.
- Published in:
- Nurse Prescribing, 2017, v. 15, n. 4, p. 182, doi. 10.12968/npre.2017.15.4.182
- By:
- Publication type:
- Article
Sipuleucel-T boosts survival vs abiraterone or enzalutamide alone: Immunotherapy was also associated with fewer emergency department visits.
- Published in:
- Urology Times, 2020, v. 48, n. 12, p. 24
- By:
- Publication type:
- Article
Multifaceted approach addresses pandemic's threat to prostate cancer care: Maker of sipuleucel-T takes steps to meet patient needs during COVID-19 crisis.
- Published in:
- Urology Times, 2020, v. 48, n. 6, p. 14
- By:
- Publication type:
- Article
2-drug combination improves outcomes in bone-metastatic prostate cancer: Results with sipuleucel-T plus radium-223 show progression-free survival of 9 months.
- Published in:
- 2020
- By:
- Publication type:
- Interview
PRACTICING IN A PROSTATE CANCER "REVOLUTION": Applying Key Insights from the PROCEED Real-World Registry to Clinical Practice.
- Published in:
- Urology Times, 2020, v. 48, n. 3, p. 48
- By:
- Publication type:
- Article
Real-world outcomes reported for sipuleucel-T.
- Published in:
- Urology Times, 2019, v. 47, n. 10, p. 20
- By:
- Publication type:
- Article
Analysis further refines delivery of new therapies for metastatic CRPC.
- Published in:
- Urology Times, 2019, v. 47, n. 9, p. 5
- By:
- Publication type:
- Article
Sipuleucel-T significantly improves OS in African-Americans vs. Caucasians.
- Published in:
- Urology Times, 2019, v. 47, n. 9, p. 4
- By:
- Publication type:
- Article
Sipuleucel-T cost lower vs. oral drugs over time: Cost to achieve additional OS benefit increases for enza, abi.
- Published in:
- Urology Times, 2019, v. 47, n. 8, p. 9
- By:
- Publication type:
- Article
Manufacturing Sipuleucel-T First FDA-approved immunotherapy for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.
- Published in:
- Urology Times, 2013, p. 2
- By:
- Publication type:
- Article
Immunotherapy for prostate cancer: recent developments and future challenges.
- Published in:
- Cancer & Metastasis Reviews, 2014, v. 33, n. 2/3, p. 641, doi. 10.1007/s10555-013-9479-8
- By:
- Publication type:
- Article
Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology.
- Published in:
- Central European Journal of Urology (2080-4806), 2021, v. 74, n. 3, p. 300, doi. 10.5173/ceju.2021.0094
- By:
- Publication type:
- Article
Pharmacotherapeutic Management of Metastatic, Castration-Resistant Prostate Cancer in the Elderly: Focus on Non-Chemotherapy Agents.
- Published in:
- Drugs & Aging, 2014, v. 31, n. 12, p. 873, doi. 10.1007/s40266-014-0224-y
- By:
- Publication type:
- Article
Sipuleucel-T: When and for Whom to Recommend It.
- Published in:
- Oncology (08909091), 2017, v. 31, n. 12, p. 900
- By:
- Publication type:
- Article
Small Steps That Lead to a Giant Leap for Prostate Cancer Patients.
- Published in:
- Oncology (08909091), 2014, v. 28, n. 8, p. 652
- By:
- Publication type:
- Article
Sipuleucel-T for the Treatment of Patients With Metastatic Castrate-resistant Prostate Cancer: Considerations for Clinical Practice.
- Published in:
- Reviews in Urology, 2015, v. 17, n. 4, p. 203, doi. 10.3909/riu0671
- By:
- Publication type:
- Article
The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.
- Published in:
- Reviews in Urology, 2014, v. 16, n. 3, p. 122, doi. 10.3909/riu0637
- By:
- Publication type:
- Article
What Nurses and Patients Need to Know About Sipulecucel-T Immunotherapy for Prostate Cancer.
- Published in:
- ONS Connect, 2015, v. 30, n. 2, p. 40
- By:
- Publication type:
- Article
Manage Immune-Related Adverse Events Associated With Cancer Immunotherapies.
- Published in:
- ONS Connect, 2014, v. 29, n. 3, p. 36, doi. 10.1188/14.CJON.311-317
- By:
- Publication type:
- Article
The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus.
- Published in:
- European Journal of Clinical Pharmacology, 2014, v. 70, n. 8, p. 983, doi. 10.1007/s00228-014-1698-6
- By:
- Publication type:
- Article
Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances.
- Published in:
- Oncologist, 2016, v. 21, n. 2, p. 233, doi. 10.1634/theoncologist.2015-0282
- By:
- Publication type:
- Article
Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Oncologist, 2013, v. 18, n. 5, p. 558, doi. 10.1634/theoncologist.2012-0478
- By:
- Publication type:
- Article
A changing landscape in castration-resistant prostate cancer treatment.
- Published in:
- Frontiers in Endocrinology, 2012, v. 3, p. 1, doi. 10.3389/fendo.2012.00085
- By:
- Publication type:
- Article
Standing Variations Modeling Captures Inter-Individual Heterogeneity in a Deterministic Model of Prostate Cancer Response to Combination Therapy.
- Published in:
- Cancers, 2021, v. 13, n. 8, p. 1872, doi. 10.3390/cancers13081872
- By:
- Publication type:
- Article
Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design.
- Published in:
- Cancers, 2020, v. 12, n. 10, p. 2908, doi. 10.3390/cancers12102908
- By:
- Publication type:
- Article
Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC).
- Published in:
- Cancers, 2020, v. 12, n. 10, p. 2831, doi. 10.3390/cancers12102831
- By:
- Publication type:
- Article
Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy.
- Published in:
- Cancers, 2019, v. 11, n. 9, p. 1314, doi. 10.3390/cancers11091314
- By:
- Publication type:
- Article
A Perspective of Immunotherapy for Prostate Cancer.
- Published in:
- Cancers, 2016, v. 8, n. 7, p. 64, doi. 10.3390/cancers8070064
- By:
- Publication type:
- Article
The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T.
- Published in:
- Cancers, 2013, v. 5, n. 2, p. 511, doi. 10.3390/cancers5020511
- By:
- Publication type:
- Article
Immunotherapy for Prostate Cancer.
- Published in:
- AUANews, 2017, v. 22, n. 1, p. 12
- By:
- Publication type:
- Article
Multidisciplinary Care for CRPC.
- Published in:
- AUANews, 2014, v. 19, n. 9, p. 1
- By:
- Publication type:
- Article
Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2015, v. 64, n. 6, p. 655, doi. 10.1007/s00262-015-1707-3
- By:
- Publication type:
- Article